Sierra Oncology to Describe Phase 1 Clinical Designs

Sierra Oncology said early Wednesday it plans to present two posters describing phase 1 clinical designs for its lead drug candidate, SRA737, at the American Society of Clinical Oncology’s annual meeting, being held in Chicago on June 5.

These ongoing trials were recently amended to include cohort expansions of prospectively selected patients with tumors identified to have genetic aberrations hypothesized to confer sensitivity to Chk1 inhibition via synthetic lethality, the company said in a press release. Sierra Oncology is a clinical stage drug development company advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer. SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and central mediator of the DDR network.

By Caroline Williams